Zacks: Analysts Expect Regeneron Pharmaceuticals Inc (REGN) to Announce $4.74 EPS

Wall Street analysts expect that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will announce earnings per share (EPS) of $4.74 for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Regeneron Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $4.14 and the highest estimate coming in at $5.35. Regeneron Pharmaceuticals posted earnings per share of $4.17 during the same quarter last year, which would indicate a positive year-over-year growth rate of 13.7%. The business is scheduled to report its next quarterly earnings report before the market opens on Thursday, August 2nd.

On average, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $18.93 per share for the current year, with EPS estimates ranging from $17.66 to $21.03. For the next financial year, analysts forecast that the company will post earnings of $21.15 per share, with EPS estimates ranging from $19.25 to $23.34. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 3rd. The biopharmaceutical company reported $4.67 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $5.08 by ($0.41). Regeneron Pharmaceuticals had a net margin of 23.54% and a return on equity of 29.92%. The business had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the prior year, the business posted $2.92 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 14.6% on a year-over-year basis.

REGN has been the topic of several recent research reports. UBS Group lowered shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, April 9th. Raymond James reaffirmed a “market perform” rating on shares of Regeneron Pharmaceuticals in a report on Monday, April 9th. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 11th. Credit Suisse Group reduced their target price on shares of Regeneron Pharmaceuticals from $440.00 to $420.00 and set a “buy” rating on the stock in a report on Tuesday, April 17th. Finally, BidaskClub lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, April 18th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $410.63.

In other Regeneron Pharmaceuticals news, Director George L. Sing sold 7,000 shares of the firm’s stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $285.29, for a total value of $1,997,030.00. Following the sale, the director now owns 127,772 shares of the company’s stock, valued at approximately $36,452,073.88. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman P Roy Vagelos sold 74,670 shares of the firm’s stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $367.22, for a total transaction of $27,420,317.40. Following the completion of the sale, the chairman now directly owns 553,121 shares in the company, valued at approximately $203,117,093.62. The disclosure for this sale can be found here. In the last three months, insiders sold 291,388 shares of company stock worth $95,611,012. Insiders own 12.42% of the company’s stock.

A number of institutional investors have recently made changes to their positions in REGN. Atria Investments LLC lifted its position in shares of Regeneron Pharmaceuticals by 10.9% in the 2nd quarter. Atria Investments LLC now owns 1,497 shares of the biopharmaceutical company’s stock worth $516,000 after purchasing an additional 147 shares during the period. World Asset Management Inc lifted its position in shares of Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. World Asset Management Inc now owns 5,284 shares of the biopharmaceutical company’s stock worth $1,823,000 after purchasing an additional 153 shares during the period. Stonebridge Capital Management Inc. lifted its position in shares of Regeneron Pharmaceuticals by 7.1% in the 2nd quarter. Stonebridge Capital Management Inc. now owns 2,499 shares of the biopharmaceutical company’s stock worth $902,000 after purchasing an additional 166 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its position in shares of Regeneron Pharmaceuticals by 0.8% in the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 22,119 shares of the biopharmaceutical company’s stock worth $7,631,000 after purchasing an additional 182 shares during the period. Finally, Pictet & Cie Europe SA lifted its position in shares of Regeneron Pharmaceuticals by 14.5% in the 1st quarter. Pictet & Cie Europe SA now owns 1,486 shares of the biopharmaceutical company’s stock worth $512,000 after purchasing an additional 188 shares during the period. 66.20% of the stock is currently owned by institutional investors and hedge funds.

Shares of Regeneron Pharmaceuticals traded down $5.99, hitting $367.60, on Friday, MarketBeat Ratings reports. 1,054,156 shares of the company’s stock traded hands, compared to its average volume of 905,037. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.94 and a current ratio of 3.59. Regeneron Pharmaceuticals has a one year low of $281.89 and a one year high of $513.42. The firm has a market cap of $40.33 billion, a P/E ratio of 27.41, a P/E/G ratio of 1.32 and a beta of 1.36.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: How Do I Invest in Dividend Stocks

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply